









Markets
/
Stocks
/
nasdaq-athe
/

Alterity Therapeutics Ltd

ATHE

3.848USD

-0.052-1.33%

Market hours （ET）Quotes delayed by 15 min

58.54MMarket Cap

--P/E TTM



Alterity Therapeutics Ltd

3.848

-0.052-1.33%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Alterity Therapeutics Ltd

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Alterity Therapeutics Ltd's Score

Industry at a Glance

Industry Ranking

290 / 501

Overall Ranking

527 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

11.000

Target Price

+194.91%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Alterity Therapeutics Ltd Highlights

StrengthsRisks

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 2511.94% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 288.77K.

Undervalued

The company’s latest PE is -6.11, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 223.02K shares, decreasing 28.45% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 131.43K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92. Its latest quarterly revenue reached 73.51K, representing a year-over-year decrease of 4.87%, while its net profit experienced a year-over-year decrease of 11.56%.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Alterity Therapeutics Ltd's Company Valuation

Currency: USD Updated: 2025-10-27

There is no valuation score for this company; the Biotechnology & Medical Research industry's average is 6.98. Its current P/E ratio is -6.11, which is -100.00% below the recent high of 0.00 and -42.12% above the recent low of -8.68.

Score

Industry at a Glance

Previous score

0.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 290/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Alterity Therapeutics Ltd is 11.00, with a high of 12.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

11.000

Target Price

+194.91%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Alterity Therapeutics Ltd

ATHE

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 7.41, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 5.20 and the support level at 3.78, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.40

Change

0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.205

Sell

RSI(14)

39.925

Neutral

STOCH(KDJ)(9,3,3)

17.960

Neutral

ATR(14)

0.293

Low Volatility

CCI(14)

-161.584

Sell

Williams %R

75.614

Sell

TRIX(12,20)

-0.065

Sell

StochRSI(14)

26.880

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

4.094

Sell

MA10

4.358

Sell

MA20

4.529

Sell

MA50

4.351

Sell

MA100

4.569

Sell

MA200

4.150

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 1.23%, representing a quarter-over-quarter decrease of 15.09%. The largest institutional shareholder is Steven Cohen, holding a total of 131.43K shares, representing 0.73% of shares outstanding, with 97.04% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Twin Lakes Capital

5.92K

Point72 Asset Management, L.P.

Star Investors

131.43K

Homrich Berg

-100.00%

Morgan Stanley & Co. LLC

58.23K

+33.46%

Greenleaf Trust

17.00K

BNP Paribas Securities Corp. North America

8.19K

-16.02%

Geode Capital Management, L.L.C.

1.16K

EverSource Wealth Advisors, LLC

628.00

Osaic Holdings, Inc.

181.00

Rhumbline Advisers Ltd. Partnership

130.00

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.16. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.